Study List:

Study 1:

NCT Number: NCT04252885

Title: The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

Acronym: ELACOI

Status: Recruiting

Study Results: No Results Available

Conditions: Coronavirus Infections

Interventions: Drug: Lopinavir and Ritonavir Tablets|Drug: Arbidol

Outcome Measures: The rate of virus inhibition|The disease prorogation-temperature|The disease prorogation-respiratory function 1|The disease prorogation-respiratory function 2|The disease prorogation-respiratory function 3

Sponsor/Collaborators: Guangzhou 8th People's Hospital

Gender: All

Age: 18 Years to 80 Years (Adult, Older Adult)

Phases: Phase 4

Enrollment: 125

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Other IDs: GZ8H-V1.0 20200122

Start Date: January 28, 2020

Primary Completion Date: May 30, 2020

Completion Date: July 31, 2020

First Posted: February 5, 2020

Results First Posted:

Last Update Posted: February 5, 2020

Locations: Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04252885

Study 2:

NCT Number: NCT02845843

Title: MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b

Acronym: MIRACLE

Status: Recruiting

Study Results: No Results Available

Conditions: Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Interventions: Drug: Combination of Lopinavir /Ritonavir and Interferon beta-1b|Drug: Placebo

Outcome Measures: 90-day mortality|Organ support-free days (e.g., supplemental O2, ventilator, extracorporeal membrane oxygenation (ECMO), renal replacement and vasopressors)|RT-PCR cycle threshold value in the lower respiratory samples|Sequential organ failure assessment (SOFA) scores|Length of stay in ICU|Length of stay in hospital|Duration of mechanical ventilation|Hospital-acquired infections as assessed by the NHSN 2016 definitions|Serial chest radiograph findings|Number of Patients with Adverse drug reactions related to the treatment|Karnofsky Performance Scale|ICU mortality|Hospital mortality|28-day mortality

Sponsor/Collaborators: King Abdullah International Medical Research Center

Gender: All

Age: 18 Years and older (Adult, Older Adult)

Phases: Phase 2|Phase 3

Enrollment: 194

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Other IDs: KingAbdullahIMRC

Start Date: July 2016

Primary Completion Date: December 2020

Completion Date: December 2020

First Posted: July 27, 2016

Results First Posted:

Last Update Posted: March 7, 2019

Locations: Intensive Care Unit, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia|King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT02845843

Study 3:

NCT Number: NCT04261907

Title: Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: 2019-nCoV

Interventions: Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group

Outcome Measures: The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal

Sponsor/Collaborators: First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceuticals Co., Ltd.

Gender: All

Age: 18 Years to 75 Years (Adult, Older Adult)

Phases: Not Applicable

Enrollment: 160

Funded Bys: Other|Industry

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Other IDs: ASC09F-CTP-ZY-01

Start Date: February 7, 2020

Primary Completion Date: May 31, 2020

Completion Date: June 30, 2020

First Posted: February 10, 2020

Results First Posted:

Last Update Posted: February 10, 2020

Locations:

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04261907

Study 4:

NCT Number: NCT04276688

Title: Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: Novel Coronavirus Infection

Interventions: Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B

Outcome Measures: Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events

Sponsor/Collaborators: The University of Hong Kong|Hospital Authority, Hong Kong

Gender: All

Age: 18 Years and older (Adult, Older Adult)

Phases: Phase 2

Enrollment: 70

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Other IDs: UW-20-074

Start Date: February 10, 2020

Primary Completion Date: January 31, 2022

Completion Date: July 31, 2022

First Posted: February 19, 2020

Results First Posted:

Last Update Posted: February 19, 2020

Locations:

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04276688

Study 5:

NCT Number: NCT04275388

Title: Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia

Acronym:

Status: Not yet recruiting

Study Results: No Results Available

Conditions: 2019 Novel Coronavirus Pneumonia

Interventions: Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization

Outcome Measures: Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia

Sponsor/Collaborators: Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Gender: All

Age: 18 Years to 70 Years (Adult, Older Adult)

Phases: Not Applicable

Enrollment: 348

Funded Bys: Industry

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Other IDs: QF-XYP2001-1

Start Date: February 14, 2020

Primary Completion Date: May 14, 2020

Completion Date: December 14, 2021

First Posted: February 19, 2020

Results First Posted:

Last Update Posted: February 19, 2020

Locations:

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04275388

Study 6:

NCT Number: NCT04251871

Title: Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection

Acronym:

Status: Recruiting

Study Results: No Results Available

Conditions: Pneumonia Caused by Human Coronavirus (Disorder)

Interventions: Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)

Outcome Measures: Time to complete remission of 2019-nCoV infection-associated symptoms|The incidence of dyspnea with low oxygen saturation level and high respiratory rate|Number of subjects who develop complications of 2019-nCoV infection|Time to virus shedding|Time to improvement of abnormalities in Chest radiology|The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment

Sponsor/Collaborators: Beijing 302 Hospital

Gender: All

Age: 14 Years to 80 Years (Child, Adult, Older Adult)

Phases: Not Applicable

Enrollment: 150

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment

Other IDs: 2020001D

Start Date: January 22, 2020

Primary Completion Date: January 22, 2021

Completion Date: January 22, 2021

First Posted: February 5, 2020

Results First Posted:

Last Update Posted: February 5, 2020

Locations: The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT04251871

Study 7:

NCT Number: NCT00578825

Title: A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

Acronym:

Status: Unknown status

Study Results: No Results Available

Conditions: Severe Acute Respiratory Syndrome

Interventions: Drug: Lopinavir / Ritonavir plus Ribavirin

Outcome Measures: Development of severe SARS|Adverse events|SARS-CoV Viral load|Immunological profile

Sponsor/Collaborators: Hospital Authority, Hong Kong

Gender: All

Age: 18 Years and older (Adult, Older Adult)

Phases: Not Applicable

Enrollment: 340

Funded Bys: Other

Study Type: Interventional

Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment

Other IDs: KW/FR/04-009|HARECCTR0500028|NTWC/CREC/349/05

Start Date:

Primary Completion Date:

Completion Date:

First Posted: December 21, 2007

Results First Posted:

Last Update Posted: August 22, 2013

Locations: Department of Health, Hong Kong, China|Kowloon Hospital, Hong Kong, China|Prince of Wales Hospital, Hong Kong, China|Princess Margaret Hospital, Hong Kong, China|Queen Mary Hospital, Hong Kong, China|The Chinese University of Hong Kong, Hong Kong, China|The University of Hong Kong, Hong Kong, China|Tuen Mun Hospital, Hong Kong, China|United Christian Hospital, Hong Kong, China

Study Documents:

URL: https://ClinicalTrials.gov/show/NCT00578825